Cargando…
Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience
In 2020, the U.S. Food and Drug Administration (FDA) enabled manufacturers to request emergency use authorization (EUA) to facilitate the rapid authorization of in vitro diagnostic (IVD) platforms for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Uncommon SARS-CoV-2...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769917/ https://www.ncbi.nlm.nih.gov/pubmed/36255326 http://dx.doi.org/10.1128/spectrum.01355-22 |
_version_ | 1784854477800472576 |
---|---|
author | Burns, Bethany L. Moody, Domonique Tu, Zheng Jin Nakitandwe, Joy Brock, Jay E. Bosler, David Mitchell, Stephanie L. Loeffelholz, Michael J. Rhoads, Daniel D. |
author_facet | Burns, Bethany L. Moody, Domonique Tu, Zheng Jin Nakitandwe, Joy Brock, Jay E. Bosler, David Mitchell, Stephanie L. Loeffelholz, Michael J. Rhoads, Daniel D. |
author_sort | Burns, Bethany L. |
collection | PubMed |
description | In 2020, the U.S. Food and Drug Administration (FDA) enabled manufacturers to request emergency use authorization (EUA) to facilitate the rapid authorization of in vitro diagnostic (IVD) platforms for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Uncommon SARS-CoV-2 point mutations could cause nucleocapsid (N) gene target failure (NGTF) when using first-generation Xpert Xpress assays, so improvements were designed and implemented. In response to NGTF reports and with consideration of viral genomic information in public databases, the Xpress assays were redesigned to mitigate the impact of SARS-CoV-2 mutations on qualitative assay performance. The second-generation assays include a third gene target (RNA-dependent RNA polymerase [RdRp]) and redundant oligonucleotide probes for the N2 target. First- and second-generation assay performances were evaluated using a challenge set of samples. A second-generation assay with updated oligonucleotide chemistry received FDA EUA in September 2021. A prototype assay with oligonucleotide chemistry similar to that of the second-generation assay with FDA EUA successfully detected all three gene targets (N2, envelope [E], and RdRp) in all challenge samples (100%; 50/50), including variants with N gene mutations (g.29197C>T or g.29200C>T), which caused NGTF in the first-generation assays. Investigation and reporting of IVD target failures, public sharing of viral genomic sequence data, and the FDA EUA pathway were essential components in facilitating a short cycle time from the identification of mutations that impact the performance of an IVD assay to the design and implementation of an improved IVD assay. IMPORTANCE The SARS-CoV-2 genome has mutated during the coronavirus disease 2019 (COVID-19) pandemic. Some of these mutations have impacted the performance of nucleic acid amplification tests like PCR, which are commonly used as diagnostic tools to detect an infection. The U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process enables the rapid reformulation and regulatory authorization of improved PCRs. In our experience, the identification of SARS-CoV-2 mutations that impact PCR performance, the subsequent development of improved PCR chemistry, and the use of the FDA EUA regulatory pathway led to improved diagnostic performance during the SARS-CoV-2 pandemic that is able to keep pace with the rapidly evolving genome of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-9769917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-97699172022-12-22 Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience Burns, Bethany L. Moody, Domonique Tu, Zheng Jin Nakitandwe, Joy Brock, Jay E. Bosler, David Mitchell, Stephanie L. Loeffelholz, Michael J. Rhoads, Daniel D. Microbiol Spectr Research Article In 2020, the U.S. Food and Drug Administration (FDA) enabled manufacturers to request emergency use authorization (EUA) to facilitate the rapid authorization of in vitro diagnostic (IVD) platforms for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Uncommon SARS-CoV-2 point mutations could cause nucleocapsid (N) gene target failure (NGTF) when using first-generation Xpert Xpress assays, so improvements were designed and implemented. In response to NGTF reports and with consideration of viral genomic information in public databases, the Xpress assays were redesigned to mitigate the impact of SARS-CoV-2 mutations on qualitative assay performance. The second-generation assays include a third gene target (RNA-dependent RNA polymerase [RdRp]) and redundant oligonucleotide probes for the N2 target. First- and second-generation assay performances were evaluated using a challenge set of samples. A second-generation assay with updated oligonucleotide chemistry received FDA EUA in September 2021. A prototype assay with oligonucleotide chemistry similar to that of the second-generation assay with FDA EUA successfully detected all three gene targets (N2, envelope [E], and RdRp) in all challenge samples (100%; 50/50), including variants with N gene mutations (g.29197C>T or g.29200C>T), which caused NGTF in the first-generation assays. Investigation and reporting of IVD target failures, public sharing of viral genomic sequence data, and the FDA EUA pathway were essential components in facilitating a short cycle time from the identification of mutations that impact the performance of an IVD assay to the design and implementation of an improved IVD assay. IMPORTANCE The SARS-CoV-2 genome has mutated during the coronavirus disease 2019 (COVID-19) pandemic. Some of these mutations have impacted the performance of nucleic acid amplification tests like PCR, which are commonly used as diagnostic tools to detect an infection. The U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process enables the rapid reformulation and regulatory authorization of improved PCRs. In our experience, the identification of SARS-CoV-2 mutations that impact PCR performance, the subsequent development of improved PCR chemistry, and the use of the FDA EUA regulatory pathway led to improved diagnostic performance during the SARS-CoV-2 pandemic that is able to keep pace with the rapidly evolving genome of SARS-CoV-2. American Society for Microbiology 2022-10-18 /pmc/articles/PMC9769917/ /pubmed/36255326 http://dx.doi.org/10.1128/spectrum.01355-22 Text en Copyright © 2022 Burns et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Burns, Bethany L. Moody, Domonique Tu, Zheng Jin Nakitandwe, Joy Brock, Jay E. Bosler, David Mitchell, Stephanie L. Loeffelholz, Michael J. Rhoads, Daniel D. Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title | Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title_full | Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title_fullStr | Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title_full_unstemmed | Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title_short | Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience |
title_sort | design and implementation of improved sars-cov-2 diagnostic assays to mitigate the impact of genomic mutations on target failure: the xpert xpress sars-cov-2 experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769917/ https://www.ncbi.nlm.nih.gov/pubmed/36255326 http://dx.doi.org/10.1128/spectrum.01355-22 |
work_keys_str_mv | AT burnsbethanyl designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT moodydomonique designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT tuzhengjin designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT nakitandwejoy designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT brockjaye designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT boslerdavid designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT mitchellstephaniel designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT loeffelholzmichaelj designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience AT rhoadsdanield designandimplementationofimprovedsarscov2diagnosticassaystomitigatetheimpactofgenomicmutationsontargetfailurethexpertxpresssarscov2experience |